A sustained decline in the Company's share price and market capitalization during the first quarter of 2026 was identified as a triggering event requiring an interim goodwill impairment test. As a result, the fair value of each reporting unit was estimated as of March 31, 2026 using the market approach, based on observable revenue multiples of guideline public companies, and the income approach. The income approach considered projected revenue and profitability of each reporting unit and a discount rate reflective of the risk-adjusted cost of capital of 17% for the Women's Health reporting unit. The Company corroborated the reasonableness of the estimated reporting unit fair values by reconciling the values to the Company's enterprise value and market capitalization, including the consideration of a control premium. Accordingly, this fair value measurement is classified as Level 3 in the fair value hierarchy because it is based primarily upon unobservable inputs that reflect management's assumptions.

As a result of the impairment test, during the three months ended March 31, 2026, the Company recognized a goodwill impairment charge of $4.5 million attributable to the Women's Health reporting unit, reducing the carrying value of goodwill for the reporting unit to its estimated fair value of zero. The goodwill impairment charge is reflected within Goodwill and long-lived asset impairment charges in the Condensed Consolidated Statements of Operations. The Company determined that the goodwill balances for the Mental Health and International reporting units were not impaired. The remaining goodwill value of $47.1 million consists of $29.8 million for the Mental Health reporting unit and $17.3 million for the International reporting unit. No goodwill impairment charges were recognized during the three months ended June 30, 2026.

Management will continue to monitor for any additional indicators of impairment in future periods. Goodwill is tested for impairment at least annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.


(in millions)	Gross Carrying Amount		Accumulated Amortization		Net
At June 30, 2026
Developed technologies	$	475.0	$	(365.2)	$	109.8
Internal-use software	21.9		(6.7)		15.2
Trademarks	2.0		(1.6)		0.4
Licensed technologies	4.5		(0.6)		3.9
Internal-use software (in-process)	9.7		—		9.7
Total intangible assets	$	513.1	$	(374.1)	$	139.0


(in millions)	Gross Carrying Amount		Accumulated Amortization		Net
At December 31, 2025
Developed technologies	$	475.9	$	(352.2)	$	123.7
Internal-use software	21.9		(4.3)		17.6
Customer relationships	2.1		(1.6)		0.5
Trademarks	4.5		(0.4)		4.1
Internal-use software (in-process)	7.5		—		7.5
Total intangible assets	$	511.9	$	(358.5)	$	153.4